Recombinant Or Stably-transformed Bacterium Encoding One Or More Heterologous Proteins Or Fragments Thereof Patents (Class 424/200.1)
  • Patent number: 11285197
    Abstract: Mesothelin can be used as an immunotherapeutic target. It induces a cytolytic T cell response. Portions of mesothelin which induce such responses are identified. Vaccines can be either polynucleotide- or polypeptide-based. Carriers for raising a cytolytic T cell response include bacteria and viruses. A mouse model for testing vaccines and other anti-tumor therapeutics and prophylactics comprises a strongly mesothelin-expressing, transformed peritoneal cell line.
    Type: Grant
    Filed: July 2, 2019
    Date of Patent: March 29, 2022
    Assignee: Johns Hopkins University
    Inventors: Elizabeth A. Jaffee, Tzyy-Choou Wu, Chien-Fu Hung, Ralph Hruban
  • Patent number: 11246919
    Abstract: The present invention refers to new glycoconjugate antigens expressing built-in multiple epitopes and to polyvalent glycoconjugate vaccines intended for the protection of mammalians, and particularly for the protection of the human population from enteropathogenic bacteria, such as the Gram-positive anaerobic bacterium Clostridium difficile and the Gram-negative bacteria Salmonella typhi, Escherichia coli, Vibrio cholerae, Shigella flexneri, Salmonella typhimurium, Salmonella enteritidis, Salmonella paratyphi A, Shigella sonnei, Shigella dysenteriae, Salmonella cholerasuis, Klebsiella, Enterobacter, Pseudomonas aeruginosa and/or from viral gastrointestinal infections due to human noroviruses.
    Type: Grant
    Filed: October 28, 2019
    Date of Patent: February 15, 2022
    Assignee: BIOSYNTH S.R.L.
    Inventor: Massimo Porro
  • Patent number: 11147883
    Abstract: A composition comprising intact killed bacterial cells that contain a therapeutic nucleic acid, a drug or a functional nucleic acid is useful for targeted delivery to mammalian cells. The targeted delivery optionally employs bispecific ligands, comprising a first arm that carries specificity for a killed bacterial cell surface structure and a second arm that carries specificity for a mammalian cell surface receptor, to target killed bacterial cells to specific mammalian cells and to cause endocytosis of the killed bacterial cells by the mammalian cells. Alternatively, the delivery method exploits the natural ability of phagocytic mammalian cells to engulf killed bacterial cells without the use of bispecific ligands.
    Type: Grant
    Filed: November 22, 2013
    Date of Patent: October 19, 2021
    Assignee: EnGenlC Molecular Delivery Pty Ltd
    Inventors: Himanshu Brahmbhatt, Jennifer MacDiarmid
  • Patent number: 11136354
    Abstract: The subject application provides a genetically modified recombinant facultative intracellular invasive bacterial pathogen (RFIIBP) or a recombinant attenuated Salmonella vaccine (RASV) strains encoding Zika virus (ZIKV) antigens. These strains exhibit high immunogenicity, complete safety, and attenuation, and are unable to persist or be shed in an infective or viable form. These RFIIBPs and RASVs also exhibit regulated delayed attenuation in vivo, regulated delayed in vivo synthesis of protective ZIKV antigens. Methods of inducing mucosal, systemic and cellular immunities in hosts are also provided and antibodies produced using the disclosed RFIIBPs and RASVs can comprise neutralizing antibodies against ZIKV that do not crossreact with Dengue virus (DENV).
    Type: Grant
    Filed: July 24, 2017
    Date of Patent: October 5, 2021
    Assignee: UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED
    Inventor: Roy Curtiss, III
  • Patent number: 11045506
    Abstract: The present invention relates to methods and compositions for identifying subjects treated with or considered for treatment with checkpoint blockade therapeutic agents that are at higher or lower risk for developing checkpoint therapy associated colitis, by analyzing the intestinal microbiome of those subjects. It is based, at least in part, on the discovery that the abundance of certain intestinal microbiota of the phyla Bacteroidetes, including the bacteria in the families Bacteroidaceae, Rikenellaceae, and Barnesisllaceae, and/or an increase or decrease in microbial genetic pathways involved in polyamine transport and/or B vitamin biosynthesis (e.g., (riboflavin (B2), pantothenate (B5) and thiamine (B1)) are associated with the likelihood of developing checkpoint therapy associated colitis.
    Type: Grant
    Filed: May 21, 2018
    Date of Patent: June 29, 2021
    Assignee: MEMORIAL SLOAN-KETTERING CANCER CENTER
    Inventors: Eric Pamer, Jedd D. Wolchok, Krista Dubin
  • Patent number: 10973892
    Abstract: Provided herein are immunogenic compositions comprising a recombinant modified vaccinia virus Ankara (MVA) comprising a nucleic acid sequence encoding a CD40 ligand (CD40L) and a nucleic acid sequence encoding a heterologous disease-associated antigen, wherein the immunogenic composition induces increases T-cell immune responses specific for the heterologous disease-associated antigen when administered to a human host, and related methods and uses.
    Type: Grant
    Filed: March 15, 2013
    Date of Patent: April 13, 2021
    Assignee: Bavarian Nordic A/S
    Inventors: Henning Lauterbach, Hubertus Hochrein
  • Patent number: 10925951
    Abstract: The present invention concerns a composition comprising at least one prophylactically or therapeutically active agent selected from the group consisting of attenuated Porphyromonas gingivalis, inactivated Porphyromonas gingivalis, a subunit of Porphyromonas gingivalis, a recombinant or isolated immunogenic polypeptide or peptide from Porphyromonas gingivalis or a c DNA from Porphyromonas gingivalis, for use as a vaccine for preventing or treating periodontitis, diabetes, obesity and/or complications thereof in a subject. The present invention also concerns an isolated antibody having specificity for Porphyromonas gingivalis for use for preventing or treating periodontitis, diabetes, obesity and/or complications thereof in a subject.
    Type: Grant
    Filed: December 15, 2016
    Date of Patent: February 23, 2021
    Assignees: INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM), UNIVERSITE PAUL SABATIER TOULOUSE III, CENTRE HOSPITALIER UNIVERSITAIRE DE MONTPELLIER
    Inventors: Vincent Blasco-Baque, Lucile Garidou, Rémy Burcelin
  • Patent number: 10801030
    Abstract: General secretory pathway (GSP) mutant Listeria bacteria are provided. Aspects of the bacteria include the presence of a GSP mutation, e.g., a SecY and/or SecA mutation. Also provided are methods of making and using the Listeria bacteria comprising a GSP mutation as vectors and vaccines expressing a heterologous nucleic acid.
    Type: Grant
    Filed: November 4, 2015
    Date of Patent: October 13, 2020
    Assignee: THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
    Inventors: Daniel A. Portnoy, Juliana Durack, Thomas P. Burke
  • Patent number: 10646561
    Abstract: The invention provides compositions and methods for using PltA, PltB, CdtB, or a mutant thereof, in inducing or enhancing an immune response.
    Type: Grant
    Filed: July 21, 2016
    Date of Patent: May 12, 2020
    Assignee: YALE UNIVERSITY
    Inventors: Jorge E. Galan, Jeongmin Song
  • Patent number: 10463719
    Abstract: Microorganisms comprising a maltose-inducible promoter and methods of use in producing biologics and introducing biologics to sites in a maltose-dependent manner. The microorganisms include a maltose-inducible promoter operably connected to a coding sequence of a biologic. The biologic may be a polypeptide or a nucleic acid. Polypeptide biologics may include lytic proteins and/or secreted proteins. Nucleic acid biologics may include antisense RNA, other types of RNA, or other types of nucleic acids. The microorganisms can be used to produce the biologics and/or introduce the biologics to in vitro or in vivo sites in a maltose-dependent manner. The microorganisms can also be used in maltose-dependent gene silencing.
    Type: Grant
    Filed: November 21, 2017
    Date of Patent: November 5, 2019
    Assignee: WISCONSIN ALUMNI RESEARCH FOUNDATION
    Inventors: Jan Peter Van Pijkeren, Jee-Hwan Oh
  • Patent number: 10426823
    Abstract: The present invention provides Listeria vaccine strains that express a heterologous antigen and a metabolic enzyme, and methods of generating same.
    Type: Grant
    Filed: June 13, 2017
    Date of Patent: October 1, 2019
    Assignee: THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA
    Inventors: Yvonne Paterson, Thorsten Verch
  • Patent number: 10370419
    Abstract: Compositions and methods directed to ESAT-6 variants which serve as vaccines for the prevention and prophylactic treatment of TB.
    Type: Grant
    Filed: December 9, 2015
    Date of Patent: August 6, 2019
    Assignee: THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXTAS SYSTEM
    Inventor: Jianjun Sun
  • Patent number: 10293039
    Abstract: Vaccines and compositions containing an attenuated L. monocytogenes prsA2 htrA deletion mutant for use in the presentation of foreign or exogenous antigens and in the treatment or prevention of diseases such as cancer or infectious disease are provided.
    Type: Grant
    Filed: April 7, 2015
    Date of Patent: May 21, 2019
    Assignees: The Board of Trustees of the University of Illinois, Montana State University
    Inventors: Nancy Freitag, Joshua Obar
  • Patent number: 10114019
    Abstract: The present invention includes a method of observing and evaluating bacterial infections within the lymph nodes of animals presented for harvest comprising: inoculating at one or more sites of an animal a known amount of a pathogen, wherein the one or more inoculation sites comprise lymph node drainage areas, and at one or more time points obtaining one or more lymph node biopsies to determine the extent of the pathogen in the lymph nodes.
    Type: Grant
    Filed: March 4, 2014
    Date of Patent: October 30, 2018
    Assignees: TEXAS TECH UNIVERSITY SYSTEM, THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY OF AGRICULTURE
    Inventors: Guy Loneragan, Thomas Edrington
  • Patent number: 10010593
    Abstract: The present invention provides methods of treating, protecting against, and inducing an immune response against a human papillomavirus-associated oropharyngeal tumor or cancer, comprising the step of administering to a subject a recombinant Listeria strain expressing a human papillomavirus antigen.
    Type: Grant
    Filed: October 14, 2015
    Date of Patent: July 3, 2018
    Assignee: The Trustees of the University of Pennsylvania
    Inventor: Yvonne Paterson
  • Patent number: 9580718
    Abstract: The present invention relates to inducing acid resistance in a bacterium and methods of increasing the acid resistance of an acid sensitive bacterium.
    Type: Grant
    Filed: June 17, 2014
    Date of Patent: February 28, 2017
    Assignee: Arizona Board of Regents on Behalf of Arizona State University
    Inventors: Roy Curtiss, III, Karen Brenneman, Kenneth Roland
  • Patent number: 9347036
    Abstract: The present invention relates to gram positive bacteria with increased stress resistance and/or improved storage characteristics. In particular, the invention relates to gram positive bacterium which accumulate intracellular trehalose. The gram positive bacterium according to the invention lack cellobiose-specific PTS system IIC component (PtcC) activity. The gram positive bacterium may further lack trehalose 6-phosphate phosphorylase (TrePP) activity. The gram positive bacterium may further overexpress trehalose transporters. The invention further relates to compositions comprising such gram positive bacterium as well as methods and uses thereof.
    Type: Grant
    Filed: September 21, 2012
    Date of Patent: May 24, 2016
    Assignee: INTREXON ACTOBIOTICS NV
    Inventors: Lothar Steidler, Karolien Van Huynegem, Klaas Vandenbroucke
  • Patent number: 9297015
    Abstract: The invention relates to compositions and methods for making and using recombinant bacteria that are capable of regulated attenuation and/or regulated expression of one or more antigens of interest.
    Type: Grant
    Filed: March 7, 2013
    Date of Patent: March 29, 2016
    Assignees: Arizona Board of Regents for and on behalf of Arizona State University, The Washington University
    Inventors: Roy Curtiss, III, Shifeng Wang, Soo-Young Wanda, Wei Kong
  • Patent number: 9200036
    Abstract: Mesothelin can be used as an immunotherapeutic target. It induces a cytolytic T cell response. Portions of mesothelin which induce such responses are identified. Vaccines can be either polynucleotide- or polypeptide-based. Carriers for raising a cytolytic T cell response include bacteria and viruses. A mouse model for testing vaccines and other anti-tumor therapeutics and prophylactics comprises a strongly mesothelin-expressing, transformed peritoneal cell line.
    Type: Grant
    Filed: November 10, 2011
    Date of Patent: December 1, 2015
    Assignee: The Johns Hopkins University
    Inventors: Elizabeth Jaffee, Ralph Hruban
  • Patent number: 9187754
    Abstract: Recombinant Bordetella pertussis strains derived from parent strain Tohama are provided. The new strains are obtained by homologous recombination using a allelic exchange vector pSS4245, which allows the replacement of sections of the bacterial chromosome without leaving any accessory mutations. The segment encoding PT subunit S1 is replaced to introduce two mutations causing inactivation of the toxic activity of PT. This strain can be further modified to express increased amounts of rPT and/or PRN. A second copy of the ptx cluster of the five PT structural genes of the ptx-ptl operon with their promoter and the ptl terminator and containing the above mutations can be inserted elsewhere on the chromosome. In addition, a second copy of the PRN gene can be inserted on the chromosome. In both cases, abandoned gene loci are selected as the insertion site to avoid the introduction of unwanted genetic alterations.
    Type: Grant
    Filed: June 19, 2014
    Date of Patent: November 17, 2015
    Assignee: BIONET-ASIA, CO. LTD.
    Inventors: Chuenchit Boonchird, Wasin Buasri, Watanalai Panbangred, Jean Petre
  • Patent number: 9138468
    Abstract: Described herein are microorganisms that are modified so that they have an increased ability to be recognized by the innate immune system of a eukaryote, relative to an unmodified microorganism. A microorganism may be a gram-negative bacterium that has been modified to produce high potency lipopolysaccharide, e.g., Yersinia pestis expressing LpxL. Such modified microorganisms may be used as vaccines for protection against an infection by the unmodified microorganism. They may also be used as delivery vehicles of one or more heterologous antigens, e.g., antigens from pathogens or those associated with a hyperproliferative eukaryotic cell.
    Type: Grant
    Filed: June 17, 2014
    Date of Patent: September 22, 2015
    Assignee: UNIVERSITY OF MASSACHUSETTS
    Inventors: Egil Lien, Jon D. Goguen
  • Patent number: 9078844
    Abstract: The present invention is related to a combination comprising a first constituent and a second constituent, wherein the first constituent is a bacterial cell which comprises at least one recombinant nucleic acid molecule encoding a phagolysosomal escape peptide or polypeptide; and wherein the second constituent is a biologically active agent. In certain embodiments, the combination is of use as a vaccine to induce an immune response in a mammal.
    Type: Grant
    Filed: October 16, 2005
    Date of Patent: July 14, 2015
    Assignee: VAKZINE PROJEKT MANAGEMENT GMBH
    Inventors: Albrecht Läufer, Bernd Eisele, Leander Grode
  • Patent number: 9062297
    Abstract: The present invention encompasses a recombinant Yersinia pestis bacterium and a vaccine comprising a recombinant Yersinia pestis bacterium.
    Type: Grant
    Filed: January 13, 2011
    Date of Patent: June 23, 2015
    Assignee: The Arizona Board of Regents for and on Behalf of Arizona State University
    Inventors: Roy Curtiss, III, Wei Sun
  • Patent number: 9050285
    Abstract: The invention encompasses a recombinant bacterium capable of eliciting an immune response against Streptococcus pneumoniae, a vaccine comprising the bacterium, and methods of using the bacterium.
    Type: Grant
    Filed: April 15, 2011
    Date of Patent: June 9, 2015
    Assignee: The United States of America National Institutes of Health (NH), U.S. Dept. of Health and Human Services (DHHS)
    Inventors: Roy Curtiss, III, Javier Santander-Morales, Soo-Young Wanda, Shifeng Wang, Karen Brenneman, Huoying Shi, Wei Xin, Qingke Kong
  • Patent number: 9040059
    Abstract: The present invention encompasses recombinant bacteria and immunogenic compositions comprising the bacteria. The immunogenic composition may be used to induce an immune response against C. perfringens.
    Type: Grant
    Filed: October 6, 2008
    Date of Patent: May 26, 2015
    Assignee: The Arizona Board of Regents for and on Behalf of Arizona State University
    Inventors: Roy Curtiss, III, Bereket Zekarias, Kenneth Roland
  • Publication number: 20150140032
    Abstract: The present invention is based on the finding that microorganisms can be modified so as to express certain factors important in generating or raising host immune responses. In particular, the invention provides modified microorganisms which, when subjected to conditions which would be expected to suppress or reduce the expression, function and/or activity of certain factors, exhibit increased (often significantly increased) expression, function and/or activity of those factors. The invention provides a modified microorganism capable of expressing at least one factor under conditions in which a wild-type (or unmodified) strain of the same microorganism, exhibits inhibited expression of the at least one factor.
    Type: Application
    Filed: May 22, 2013
    Publication date: May 21, 2015
    Inventor: Michael Fontaine
  • Publication number: 20150139940
    Abstract: The invention relates to prokaryotic expression cassettes comprising a stress-regulated promoter, the promoter of the GroESL operon of Lactococcus lactis. Said cassettes can be used for the expression of genes of interest in gram-positive bacteria, and especially for producing and releasing a protein of interest when the bacteria are administered to an individual.
    Type: Application
    Filed: May 15, 2013
    Publication date: May 21, 2015
    Inventors: Luis Bermudez Humaran, Philippe Langella, Pascale Kharrat
  • Patent number: 9034345
    Abstract: The present invention generally provides methods and compositions for eliciting an immune response against Neisseria spp. bacteria in a subject, particularly against a Neisseria meningitidis serogroup B strain.
    Type: Grant
    Filed: January 23, 2006
    Date of Patent: May 19, 2015
    Assignee: Children's Hospital & Research Center Oakland
    Inventors: Dan M. Granoff, Victor Chen-Hsi Hou
  • Publication number: 20150125485
    Abstract: Provided herein are prime-boost regimens and materials used therein. The prime-boost regimens enhance the immune response to a target antigen. The vaccines used for boost are comprised of recombinant attenuated metabolically active Listeria that encodes an expressible antigen that is cross-reactive with the target antigen. In some examples, the immune response is a cellular immune response.
    Type: Application
    Filed: January 5, 2015
    Publication date: May 7, 2015
    Inventors: Thomas W. Dubensky, JR., Dirk G. Brockstedt, Meredith Lai Ling Leong, Keith S. Bahjat
  • Publication number: 20150125480
    Abstract: The present invention provides Listeria vaccine strains that express a heterologous antigen and a metabolic enzyme, and methods of generating same.
    Type: Application
    Filed: November 10, 2014
    Publication date: May 7, 2015
    Inventors: YVONNE PATERSON, THORSTEN VERCH
  • Patent number: 9017660
    Abstract: This invention provides compositions and methods for treating and vaccinating against an Her2/neu antigen-expressing tumor and inducing an immune response against dominant in a non-human animal.
    Type: Grant
    Filed: August 16, 2011
    Date of Patent: April 28, 2015
    Assignees: Advaxis, Inc., The Trustees of the University of Pennsylvania
    Inventors: Vafa Shahabi, Anu Wallecha, Paulo C. Maciag, Yvonne Paterson, Nicola Mason, Matthew Seavey
  • Publication number: 20150098964
    Abstract: This invention provides methods and compositions for using a live attenuated Listeria for inhibiting cell-mediated suppression of anti-disease infiltrating T lymphocytes in a subject having the disease.
    Type: Application
    Filed: March 12, 2013
    Publication date: April 9, 2015
    Inventors: Reshma Singh, Anu Wallecha
  • Patent number: 8992935
    Abstract: The present invention relates to a means of controlling infection persistence of Helicobacter pylori (H. pylori). In particular, the present invention relates to an isolated, genetically modified Helicobacter pylori comprising a functional urease, wherein the contiguous amino acid sequence between amino acid 529 and amino acid 555 of SEQ ID NO:1 is altered to produce said modified Helicobacter pylori which is unable to establish or maintain a persistent infection.
    Type: Grant
    Filed: June 24, 2011
    Date of Patent: March 31, 2015
    Assignee: Ondek Pty. Ltd.
    Inventors: Mohammed Benghezal, Tobias Schoep, Alma Fulurija, Douglas E. Berg, Barry J. Marshall
  • Publication number: 20150079034
    Abstract: The present invention provides recombinant Listeria strains comprising an angiogenic factor, recombinant polypeptides comprising an angiogenic factor operatively linked to a polypeptide comprising a PEST-like sequence, recombinant nucleotide molecules encoding same, related vaccines, and immunogenic and therapeutic methods utilizing same.
    Type: Application
    Filed: June 13, 2014
    Publication date: March 19, 2015
    Inventors: Matthew SEAVEY, Yvonne Paterson, Paulo Maciag, Duane Sewell
  • Publication number: 20150064215
    Abstract: Therapeutic methods for cancer treatments using a combined prokaryotic-eukaryotic delivery and expression system for the delivery of multiple therapeutic factors via a modified tumor-targeted bacteria. A targeted bacteria-vector system elicits an inter-kingdom dual expression (IKDE) of antitumor agents, in the nucleus or cytoplasm of eukaryotic cells, with priming and maintenance of the vector in the bacterium. The therapeutic factors include small interfering RNAs, tumoricidal proteins, DNA molecules, or a combination thereof. The system provides direct killing of tumor cells and alters the tumor microenvironment by expressing anti-angiogenic factors and cytokines in intracellular and/or extracellular environments. Also provided are methods of using natural exosomes comprising cargoes obtained from the bacterially infected cells. The bacteria-vector system is useful for many types of tumor and cancer as well as recombinant vaccines.
    Type: Application
    Filed: September 5, 2013
    Publication date: March 5, 2015
    Applicant: The University of Hong Kong
    Inventors: Jian-Dong Huang, Lei Shi, Bin Yu
  • Patent number: 8968748
    Abstract: The present invention generally provides methods and compositions for eliciting an immune response against Neisseria spp. bacteria in a subject, particularly against a Neisseria meningitidis serogroup B strain.
    Type: Grant
    Filed: October 21, 2011
    Date of Patent: March 3, 2015
    Assignee: Children's Hospital & Research Center Oakland
    Inventors: Dan M. Granoff, Victor Chen-Hsi Hou
  • Patent number: 8968719
    Abstract: The invention relates to Salmonella typhi Ty21a comprising core-linked Shigella dysenteriae serotype 1 O-specific polysaccharide (O-Ps) and DNA encoding O antigen biosynthesis, said DNA selected from the group consisting of: a) the DNA sequence set out in any one of SEQ ID NOs: 1 and 2 and species homologs thereof; b) DNA encoding Shigella dysenteriae serotype 1 polypeptides encoded by any one of SEQ ID NOs: 1 and 2, and species homologs thereof; and c) DNA encoding a O antigen biosynthesis gene product that hybridizes under moderately stringent conditions to the DNA of (a) or (b); and related sequences, compositions of matter, vaccines, methods of using, and methods of making.
    Type: Grant
    Filed: December 31, 2013
    Date of Patent: March 3, 2015
    Assignee: The United States of America, as represented by the Secretary, Department of Health and Human Sevices
    Inventors: Dennis J. Kopecko, De-Qi Xu
  • Publication number: 20150056246
    Abstract: The present invention relates to a probiotic cell transformed with a construct suitable to overexpress and display on the surface of the probiotic cell a fusion protein comprising at least a portion of a transport protein coupled to at least a portion of one or more antigenic proteins or peptides. Probiotic-derived vesicles displaying this fusion protein as well as methods of inducing an immune response using the probiotic cells or vesicles are also disclosed.
    Type: Application
    Filed: March 13, 2013
    Publication date: February 26, 2015
    Inventors: David A. Putnam, Joseph Rosenthal, Chung-Jr Huang, Matthew Delisa, Susana Mendez
  • Publication number: 20150056232
    Abstract: The present invention provides a recombinant bacterium and methods of using the recombinant bacterium to induce a cellular immune response.
    Type: Application
    Filed: March 14, 2013
    Publication date: February 26, 2015
    Applicant: The Arizona Board of Regents for and on behalf of Arizona State University
    Inventor: Roy Curtiss, III
  • Publication number: 20150044256
    Abstract: The present invention relates to vaccines for control of Borrelia infections in animal and human populations. In particular, the present invention provides compositions and methods comprising recombinant bacteria engineered to express one or more Borrelia burgdorferi antigens for use as Lyme disease vaccines. In some embodiments, the recombinant bacteria are freeze-dried.
    Type: Application
    Filed: August 27, 2014
    Publication date: February 12, 2015
    Inventors: Raymond J. Dattwyler, Maria Gomes-Solecki
  • Publication number: 20150037369
    Abstract: Site-specific Listeria integration vectors and methods for their use are provided. The subject vectors include a bacteriophage integrase gene and a bacteriophage attachment site, where in many embodiments the bacteriophage that is the source 0 of these elements is a listeriophage. In certain embodiments, the subject vectors further include a multiple cloning site, where the multiple cloning site may further include a polypeptide coding sequence, e.g., for a heterologous antigen. The subject vectors and methods find use in a variety of different applications, including the study of Listeria species and the preparation of Listeria vaccines.
    Type: Application
    Filed: September 12, 2014
    Publication date: February 5, 2015
    Inventors: Daniel A. Portnoy, Richard Lane Calendar, Peter M. Lauer
  • Patent number: 8945587
    Abstract: The present disclosure generally relates to genetic engineering of bacteria. More particularly, the present disclosure relates to genetic engineering of Gram-negative bacteria expressing different species of lipid A on their surface. In one embodiment, the present disclosure provides for an engineered strain of E. coli according to Table 1. In another embodiment, the present disclosure provides for a lipopolysaccharide purified from an engineered strain of E. coli according to Table 1.
    Type: Grant
    Filed: February 28, 2013
    Date of Patent: February 3, 2015
    Assignee: The Board of Regents of The University of Texas System
    Inventors: M. Stephen Trent, Brittany Needham, David Giles, Marvin Whiteley
  • Publication number: 20150017204
    Abstract: The present invention relates to gram-negative bacterial mutants resistant to one or more stress conditions, including, but not limited to, CO2, acid pH, and high osmolarity. The present invention also relates more particularly to gram-negative bacterial mutants with reduced TNF-? induction having a mutation in one or more lipid biosynthesis genes, including, but not limited to msbB, that are rendered stress-resistant by a mutation in the zwf gene. The present invention provides compositions comprising one or more stress-resistant gram-negative bacterial mutants, preferably attenuated stress-resistant gram-negative bacterial mutants. In particular, the present invention relates to methods for prophylaxis or treatment of a virally induced disease in a subject comprising administering to said subject one or more stress-resistant gram-negative bacterial mutants, preferably attenuated stress-resistant gram-negative bacterial mutants.
    Type: Application
    Filed: February 4, 2014
    Publication date: January 15, 2015
    Applicant: AVIEX TECHNOLOGIES LLC
    Inventor: David Gordon Bermudes
  • Patent number: 8932846
    Abstract: Recombinant immunogenic compositions, and methods for the manufacture and use, are provided for the prevention and treatment of intracellular pathogen diseases in humans and animals. The recombinant immunogenic compositions express high levels of recombinant proteins in vectors that do not harbor an antibiotic resistance marker (“unmarked”).
    Type: Grant
    Filed: June 12, 2008
    Date of Patent: January 13, 2015
    Assignee: The Regents of the University of California
    Inventors: Marcus A. Horwitz, Michael V. Tullius
  • Publication number: 20140363465
    Abstract: Mycobacterium bovis BCG is a potent stimulator of the cellular immune response and has potential as a recombinant vaccine vector. Disclosed are BCG strains that generate greater MHC class I presentation of a transgenic protein, relative to the unmutated parental strain, and that improve a recipient's CD8+ T cell response against the transgenic protein following vaccination. The mycobacterial constructs and their respective t/ansposon mutant BCG strains exhibit increased immunogenicity that is several times greater than responses generated by the parental strain and other existing modified rBCG strains. Furthermore, upon introducing the SIV gag gene into these novel strains, we observed that these strains primed for increased CD8+ T cell responses in a heterologous prime/boost regimen, comparable to levels generated by plasmid DNA vaccines. Creation of a second generation rBCG vector that may be utilized as a vaccine vector for immunizing against a variety of pathogens.
    Type: Application
    Filed: April 4, 2012
    Publication date: December 11, 2014
    Applicant: Beth Israel Deaconess Medical Center, Inc.
    Inventors: Norman L Letvin, Michael W. Panas, Geoff Gillard
  • Patent number: 8906664
    Abstract: The present invention provides Listeria vaccine strains that express a heterologous antigen and a metabolic enzyme, and methods of generating same.
    Type: Grant
    Filed: August 15, 2005
    Date of Patent: December 9, 2014
    Assignee: The Trustees of the University of Pennsylvania
    Inventors: Yvonne Paterson, Thorsten Verch
  • Patent number: 8889121
    Abstract: The present invention encompasses a recombinant bacterium comprising a regulated rfaH nucleic acid, as well as a vaccine comprising said recombinant bacterium. Other embodiments of the present invention encompass a recombinant bacterium comprising a regulated rfaH nucleic acid and a regulated rfc nucleic acid, while additional embodiments encompass a recombinant bacterium comprising a regulated rfaH nucleic acid and at least one nucleic acid encoding at least one exogenous antigen.
    Type: Grant
    Filed: January 21, 2011
    Date of Patent: November 18, 2014
    Assignee: The Arizona Board of Regents for an on Behalf of Arizona State University
    Inventors: Roy Curtiss, III, Qingke Kong
  • Publication number: 20140335125
    Abstract: A process for obtaining an adapted strain of Pseudomonas includes the following steps: deleting the genes ExoS, ExoT, aroA and IasI in an initial Pseudomonas strain cultivated in a LB medium; progressively cultivating this strain in a chemically defined medium based on a glucose minimal medium supplemented with magnesium and calcium; wherein the adapted strain presents the same toxicity and secretion capacities than the initial strain, and its doubling time when cultivated in the chemically defined medium is less than 60 minutes. An adapted strain is furthermore treated to become ‘killed but metabolically active’.
    Type: Application
    Filed: December 12, 2012
    Publication date: November 13, 2014
    Applicants: UNIVERSITE JOSEPH FOURIER - GRENOBLE 1, CENTRE HOSPITALIER UNIVERSITAIRE GRENOBLE
    Inventors: Audrey Le Gouellec, Bertrand Toussaint, Benoît Polack
  • Publication number: 20140335120
    Abstract: Provided herein are recombinant Listeria strains expressing a tumor-specific antigenic polypeptide and, optionally, an angiogenic polypeptide wherein a nucleic acid molecule encoding at least one of the polypeptides is operably integrated into the Listeria genome in an open reading frame with a nucleic acid sequence encoding a PEST-containing polypeptide, methods of preparing same, and methods of inducing an immune response, and treating, inhibiting, or suppressing cancer or tumors comprising administering same.
    Type: Application
    Filed: July 25, 2014
    Publication date: November 13, 2014
    Inventors: Paulo MACIAG, Anu Wallecha, Vafa Shahabi
  • Publication number: 20140322230
    Abstract: The present invention relates to the induction of tolerance to antigens, by mucosal, preferably oral delivery of the antigen in combination with an immunomodulating compound producing micro-organism. More specifically, the invention relates to the induction of Foxp3+ and/or IL-10 and/or TGF-? producing regulatory T-cells, capable of suppressing undesired immune responses toward an antigen, by oral delivery of said antigen in combination with an immunosuppressing cytokine secreting micro-organism.
    Type: Application
    Filed: March 17, 2014
    Publication date: October 30, 2014
    Applicant: ActoGeniX N.V.
    Inventors: Pieter Rottiers, Veerle Snoeck